CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy · Terms of Service · Privacy FAQ

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
StandardX›
Library
StandardX

StandardX

London deep-tech company building an accelerator-based isotope refinery for medicine and fusion.

Operating headquarters
London, England, GB🇬🇧
Founded
2025
Loading
Overview
Compare
Fundraising
Employees
News
Library

StandardX - Library

Official pages and third-party coverage in one index.

standardx.tech·16 items across 10 mapped pages · Crawled Oct 2, 2026·

Topics

Publication type

Content origin
Row density

Official pages and third-party coverage in one index

Product

4 pages
  1. Fusion/fusion

    Tritium, a key ingredient in the pursuit of fusion energy, does not exist in nature in commercially useful quantities and must be manufactured. We'll create it.

  2. Industrial/industrial

    Industrial radioisotopes span manufacturing, security and defence, environmental science, and advanced technology. We'll make more of them.

  3. Medical/medical

    Medical isotopes are the radioactive materials at the heart of nuclear medicine. We produce more of them.

  4. Technology/technology

    We’re producing critical isotopes using a novel, high-power accelerator to that is high-yield, versatile and easy to deploy.

Press

1 page
  1. News/news-media

    Read the latest news and updates from the world's first isotope refinery.

Careers & Hiring

1 page
  1. Careers/careers

    StandardX is building the world's first scalable isotope production platform. Join us.

About

1 page
  1. About us/about-us

    Our mission is to create the isotopes the world needs to improve cancer care, ensure industrial resilience and meet future energy needs.

Contact

1 page
  1. Get in touch/contact

Homepage

1 page
  1. Homepage/

    StandardX is building the isotope infrastructure the 21st century economy depends on; from medical isotopes to tritium.

Privacy

1 page
  1. Privacy Policy/privacy-notice

Not yet classified

1 page
  1. standardx.tech/

    StandardX is building the isotope infrastructure the 21st century economy depends on; from medical isotopes to tritium.

Coverage

5 items
  1. StandardX raises £10M to build a UK isotope refinery for cancer care and fusiontechfundingnews.com/standardx-10m-seed-isotope-refinery-cancer-fusion/

    London-based deeptech startup StandardX raises £10 million in seed funding led by Vsquared Ventures and East X Ventures. The company plans to use the capital to establish a UK isotope refinery producing rare radioactive materials for cancer care and future fusion energy.

    Sep 2026 · Tech Funding NewsNews article

  2. StandardX launches with £10M to expand isotope production for medicine and fusiontech.eu/2026/09/23/standardx-launches-with-ps10m-to-expand-isotope-production-for-medicine-and-fusion/

    London deep-tech company StandardX raises a £10 million seed round co-led by Vsquared Ventures and East X Ventures to build an accelerator-based isotope refinery. The planned refinery aims to expand isotope production for medicine and fusion.

    Sep 2026 · Tech.euNews article

  3. StandardX secures £10M to scale rare isotope production across medicine and fusioneuropacircuit.com/scene/standardx-secures-ps10m-to-scale-rare-isotope-production-across-medicine-and-fusion

    London-based deeptech startup StandardX raises £10 million in seed funding to scale rare-isotope production by building accelerator-based refineries. The facilities could help address critical shortages of rare isotopes used in cancer treatment and in fusion energy development.

    Sep 2026 · Europa NowNews article

  4. StandardX lands £10M to develop scalable isotope productionvestbee.com/insights/articles/standard-x-lands-10-m

    UK-based deeptech company StandardX raises £10 million in a seed round co-led by Vsquared Ventures and East X Ventures to build a scalable isotope production platform. The round also includes participation from firstminute capital, UKI2S, Brevan Howard Macro Venture, and Geometry.

    Sep 2026 · VestbeeNews article